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Research
About 80% of the 700,000 estimated annual 
cases of hepato cellular carcinoma (HCC) 
occur in low-resource, inter tropical areas, 
mainly in sub-Saharan Africa and Southeast 
Asia (McGlynn and London 2005; Sherman 
2005). The two major risk factors, chronic 
hepatitis B virus (HBV) infection and exposure 
to aflatoxin B1 (AFB1), have been classified 
as group 1 carcinogens by the International 
Agency for Research on Cancer (IARC 1994, 
2002), with a synergistic effect on HCC risk 
(Kew 2003). Both factors are preventable in 
principle (Wild and Hall 2000). The presence 
of a specific AGG → AGT mutation induced 
by AFB1 at codon 249 of TP53 tumor sup-
pressor gene (R249S) is observed in > 50% of 
HCC in geographic areas with high incidence. 
Worldwide, there is a remarkable ecological 
correlation among AFB1 exposure, incidence 
of HCC, and prevalence of the TP53 R249S 
mutation in HCC tumors (Gouas et al. 2009). 
This mutation occurs early in the pathway 
leading to HCC and may thus provide an 
early biomarker of AFB1 exposure and hepato-
carcinogenesis (Jackson et al. 2003).
Several studies have shown that plasma 
or serum of cancer patients contains signifi-
cant amounts of circulating cell-free DNA 
(CFDNA), which often carries mutations 
and epi genetic alterations identical to those 
detected in tumor tissues (Gormally et al. 
2007). Although the mechanisms of release 
and the stability of mutant DNA in the 
bloodstream are still unclear, CFDNA may 
serve as a convenient biomarker in cancer 
subjects. Importantly, traces of free fragments 
of DNA are also detectable in most healthy 
subjects (Gormally et al. 2007). In several 
instances, this DNA has been found to har-
bor mutations that predict cancer occurrence 
(Gormally et al. 2006; Jackson et al. 2003).
Double mutations in the HBV X gene 
(adenine to thymine, 1762T; and guanine 
to adenine, 1764A) have been observed in 
HCC and liver cirrhosis (Arbuthnot and 
Kew 2001; Baptista et al. 1999; Hou et al. 
1999). This mutation is also detectable in 
CFDNA up to 5 years before HCC diag-
nosis (Kuang et al. 2004; Yuan et al. 2009). 
HCC risk is increased in chronic carriers with 
1762T/1764A mutations, and it increases with 
higher serum concentrations of 1762T/1764A 
(Yuan et al. 2009).
In prospective studies in China, R249S 
was detected in the plasma of asymptomatic 
HBV carriers up to several years before HCC 
diagnosis (Jackson et al. 2003). In a case–
control study in the Gambia, West Africa, 
we used a quantitative method to detect the 
R249S mutation by electro spray mass spec-
trometry [short oligo nucleo tide mass analysis 
(SOMA)] (Lleonart et al. 2005). Plasma con-
centrations of R249S were increased in HCC 
cases (median, 2,800 copies/mL; range, 500–
11,000 copies/mL) compared with controls 
(median, 500 copies/mL; range, 250–2,000 
copies/mL). However, low levels of R249S 
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Background: Chronic hepatitis B virus (HBV) infection and dietary aflatoxin B1 (AFB1) exposure 
are etiological factors for hepato cellular carcinoma (HCC) in countries with hot, humid climates. 
HCC often harbors a TP53 (tumor protein p53) mutation at codon 249 (R249S). In chronic carriers, 
1762T/1764A mutations in the HBV X gene are associated with increased HCC risk. Both mutations 
have been detected in circulating cell-free DNA (CFDNA) from asymptomatic HBV carriers.
oBjective: We evaluated seasonal variation in R249S and HBV in relation to AFB1 exposure.
Methods: R249S was quantitated by mass spectrometry in CFDNA in a cross-sectional survey of 
473 asymptomatic subjects (237 HBV carriers and 236 non carriers) recruited in three villages in the 
Gambia over a 10-month period. 1762T/1764A HBV mutations were detected by quantitative poly-
merase chain reaction. In addition, the HBV S gene was sequenced in 99 subjects positive for HBV 
surface antigen (HBsAg). 
results: We observed a seasonal variation of serum R249S levels. Positivity for R249S and aver-
age concentration were significantly higher in HBsAg-positive subjects surveyed during April–July 
(61%; 5,690 ± 11,300 R249S copies/mL serum) than in those surveyed October–March [32% and 
480 ± 1,030 copies/mL serum (odds ratio = 3.59; 95% confidence interval: 2.05, 6.30; p < 0.001)]. 
Positivity for HBV e antigen (HBeAg) (a marker of HBV replication) and viral DNA load also 
varied seasonally, with 15–30% of subjects surveyed between April and June HBeAg posi tive, 
compared with < 10% surveyed during other months. We detected 1762T/1764A mutations in 8% 
of carriers, half of whom were positive for R249S. We found HBV geno type E in 95 of 99 HBsAg-
positive subjects.
conclusion: R249S is detectable in CFDNA of asymptomatic subjects. Evidence of temporal and 
quantitative variations suggests an interaction among AFB1 exposure, HBV positivity, and replica-
tion on TP53 mutation formation or persistence.
key words: 1762T/1764A, circulating DNA, mycotoxin, seasonality, TP53 mutation. Environ 
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(> 500 copies/mL) were detected in 46% of 
asymptomatic controls, which suggests that the 
mutation may also serve as a marker of on going 
exposure to aflatoxin (Lleonart et al. 2005).
In the Gambia, chronic HBV infection 
is endemic, affecting 11–16% of the adult 
population (Kirk et al. 2006). AFB1 exposure 
also is widespread, and the annual incidence 
of HCC peaks at 80 cases per 100,000 among 
35- to 55-year-old males (Bah et al. 2001). 
R249S was detectable in the plasma of 40% 
of HCC patients, with a concordance of 88% 
between plasma and tumor DNA (Szymañska 
et al. 2004). R249S was also found in 15% of 
patients with liver cirrhosis and in 3% of con-
trol subjects with no detected liver disease (Kirk 
et al. 2005). Furthermore, the 1762T/1764A 
HBV mutation was found in 48% (10 of 21) 
of asympto matic carriers, 75.4% (86 of 114) of 
HCC patients, and 77% (33 of 43) of patients 
with cirrhosis (Mendy et al. 2008). This muta-
tion has also been found in the serum of 66% 
of HCC patients and 11% of asymptomatic 
carriers from South Africa (Baptista et al. 
1999). These observations led us to hypothe-
size that circulating R249S may be a biomarker 
of early liver disease or, alternatively, a bio-
marker of on going AFB1 exposure, and to 
further assess the prevalence of 1762T/1764A 
mutation in asymptomatic subjects from the 
Gambia who are positive for HBV surface anti-
gen (HBsAg). Therefore, we evaluated seasonal 
variation in R249S and HBV in relation to 
AFB1 exposure.
Materials and Methods
Study participants. A total of 473 asympto-
matic study participants were recruited from 
the population of three rural villages in the 
Gambia (Keneba, Manduar, and Katong-
Kunda) where exposure to aflatoxin is wide-
spread and well documented; a previous study 
in Keneba in the Gambia showed a correla-
tion between  measurement of dietary intake 
of aflatoxin and levels of albumin-bound afla-
toxin in serum (Wild et al. 1992). These vil-
lages are part of a long-term quadrennial survey 
program for HBV infection initiated in the 
early 1980s as a pilot and sentinel program for 
the Gambian Hepatitis Intervention Study 
(Whittle et al. 2002). In this rural population, 
dietary exposure is widespread because of the 
use of groundnuts as the main basis of diet, 
whereas exposure to other HCC risk factors 
such as alcohol is negligible. We used a series 
of serum specimens (n = 491) collected for 
the survey from October 2002 to July 2003 
(van der Sande et al. 2006) to assemble a case–
control study including 237 HBsAg-positive 
(HBV carriers) and 236 HBsAg-negative (non-
carriers) individuals matched by date of sam-
pling, age, and sex. Previous studies have shown 
that serum or plasma are both suitable sources 
of CFDNA (reviewed by Gormally et al. 2007). 
None of the participants had a clinical diagnosis 
of chronic liver disease at the time of sampling, 
although no detailed clinical assessment of their 
liver status was conducted. All participants gave 
informed consent for inclusion in the quadren-
nial survey. The present protocol was reviewed 
and approved by the ethical review boards of 
the Medical Research Council in the Gambia 
and of IARC. This study complied with all 
international standards.
HBV serology. We tested subjects for HBV 
core antibodies (anti-HBc) and, if positive, 
HBsAg and HBV e antigens (HBeAg). Anti-
HBc was meas ured using the radio immuno-
assay AB-COREK test kit (Sorin Biochemica, 
Saluggia, Italy) according to the manufac-
turer’s protocol. Anti-HBc positive samples 
were tested for HBsAg by reverse passive 
hemagglutination assay (Wellcotest®; Murex 
Diagnostics, London, UK) and/or by the 
Determine™ HBsAg immuno chromatographic 
assay (Abbott Laboratories, Abbott Park, IL, 
USA). HBsAg-positive subjects were tested 
for HBeAg using an enzyme immuno assay 
(Equipar Diagnostici, Rome, Italy).
CFDNA extraction and quantitation. 
CFDNA was extracted from 300 μL serum 
using the QIAmp DNA Blood Mini Kit 
(Qiagen, Hilden, Germany) according to the 
protocol described previously (Szymañska 
et al. 2004). DNA was eluted in 200 μL 
elution buffer. Quantitation of extracted 
CFDNA was performed by fluorimetry using 
PicoGreen (Interchim, Montluçon, France).
Quantitation of R249S in CFDNA. 
R249S was quantitated by SOMA as described 
previously (Lleonart et al. 2005), with the fol-
lowing modifications. Before polymerase chain 
reaction (PCR) amplification of a 93-base-pair 
segment of exon 7 of TP53 encompassing 
codon 249, 228 copies of an internal stan-
dard plasmid were added to all DNA extracts 
to provide a reference for quantitation. After 
restriction digestion with HaeIII, which specifi-
cally cuts the wild-type sequence of codon 249, 
the mutated and internal-standard–enriched 
PCR products were reamplified, cut with GsuI 
to produce short 8-mer oligonucleotides, puri-
fied, and quantitated by HPLC/electrospray 
ionization mass spectrometry. Results were 
expressed as concentrations (copies of R249S 
per milliliter of serum). Levels ranged from 
non detectable to 63,800 copies/mL. The 
elimination of the wild-type sequence of 
codon 249 by restriction digestion increased 
the sensitivity of the method relative to the 
original method described by Lleonart et al. 
(2005). Consequently, the limit of detection 
was 70 copies/mL serum. Samples with serum 
concentrations > 70 copies/mL were classified 
as positive for R249S.
HBV DNA quantitation and 1762T/1764A 
analysis. We performed HBV DNA quantita-
tion as described previously (Mendy et al. 2006). 
1762T/1764A mutation analysis was performed 
by quantitative PCR (Yuan et al. 2009).
S gene sequencing. Analysis of the S gene 
provides geno type information that signifi-
cantly matches analysis of the entire genome 
(Hussain et al. 2003; Norder et al. 1993). 
We developed a new semi-nested PCR ampli-
fying the entire S gene. The first reaction 
was achieved on 5 μL DNA with primers 
S_HBVpol1 (5´-cctgctggtggctccagttca-3´) and 
S_HBVporv2 (5´-aaagcccaaaagacccacaat-3´); 
round settings were 95°C (15 min); 40 cycles 
of 95°C (30 sec), 60°C (30 sec), 72°C (1 min); 
and then 72°C for 7 min. The second step 
used 1 μL first reaction product and primers 
S_HBV123s (5´-tcgaggattggggaccctg-3´) 
and S_HBVporv2; round settings were 95°C 
(15 min); 45 cycles of 95°C (30 sec), 58°C 
(30 sec), 72°C (1 min); and then 72°C for 
7 min. PCR products (5 μL) were purified 
using standard ExoSap-IT® enzyme, (USB® 
Corporation, Cleveland, OH, USA) and 
nucleo tide sequences were determined for 
both strands by automated dideoxy sequencing 
(AbiPrism 3100 sequencer; Applied Biosystems, 
Carlsbad, CA, USA). Direct sequencing on 
amplified fragments was performed using the 
primers S_HBV123s, S_HBVporv2, and 
Table 1. Descriptive characteristics of participants 
in the study grouped by HBsAg status.
Characteristic
HBsAg  
positive
HBsAg 
negative
No. of subjects 237 236
Mean age (range), years 31 (5–69) 31 (5–70)
Sex [n (%)]
Male 109 (46) 108 (46)
Female 128 (54) 128 (54)
Marker of viral replication [male/female, n (%)]
HBeAg positive 17/10 (16/8) —
HBeAg negative 92/118 (84/92) —
HBV vaccination [n (%)]
Unknown 2 (1) —
Yes 17 (7) 104 (44)
No 218 (92) 132 (56)
Village [n (%)]
Keneba 89 (38) 123 (52)
Manduar 95 (40) 66 (28)
Katong-Kunda 41 (17) 36 (15)
Other 12 (5) 11 (5)
Table 2. Subjects positive for serum R249S mutation by season [n/total (%)].
Period HBsAg negativea HBsAg positive OR (95% CI)
October–July 58/236 (25) 106/237 (45) 2.49 (1.68, 3.69)b
October–March (higher AFB1 exposure) 45/134 (34) 43/134 (32) 0.94 (0.56, 1.57)
April–July (lower AFB1 exposure) 13/102 (13) 63/103 (61) 10.9 (5.35, 22.34)
ORs are adjusted for age and sex. 
aUsed as reference category for OR determination. bAdjusted for seasonality. 
AFB1 seasonality-induced TP53 mutation in CFDNA
Environmental Health Perspectives • volume 119 | number 11 | November 2011 1637
S_HBV778r (5´-gaggtataaagggactcaag-3´). 
HBV geno types and subtypes were deter-
mined in collaboration with the Virological 
Department of Swedish Institute for Infectious 
Disease.
Statistical analysis. Values were expressed in 
numbers of R249S copies/mL serum, with result-
ing values between 0 and 63,800 copies/mL. 
For statistical analyses, values below the detec-
tion limit of 70 copies/mL were assigned a value 
of 70 copies/mL. Results showed large varia-
tions and were analyzed in three ways. First, we 
evaluated the distribution of values according to 
month of collection. Second, means ± SDs were 
calculated for groups of months corresponding 
to two periods of different levels of exposure to 
aflatoxin. Third, the number and percentage of 
subjects with values > 70 copies/mL were tabu-
lated in relation with HBV serological status or 
the two periods of different aflatoxin exposure. 
To analyze the impact of seasonal AFB1 expo-
sure, we grouped results into two seasons: a) a 
higher AFB1 exposure period from October 
2002 to March 2003, after the September–
October harvest and including the dry season in 
February–March; and b) a lower AFB1 exposure 
period from April 2003 to July 2003, which 
included part of the June–August wet season. 
AFB1 accumulates in foodstuffs (principally 
groundnuts in the Gambia) after harvest in 
September–October; levels of AFB1–albumin 
adducts (a biomarker of recent AFB1 exposure) 
have been shown to decrease from their high-
est levels in the February–March dry season to 
reach their lowest levels after the June–August 
wet season just before the next harvest (Turner 
et al. 2000; Wild et al. 2000). Statistical anal-
yses were performed using STATA software 
(version 11.1; StataCorp LP, College Station, 
TX, USA) or by Student’s t-test to compare 
the average of R249S copies per milliliter in 
HBsAg-positive or -negative subjects depending 
on AFB1 exposure. Analysis involved standard 
unconditional logistic regression of the prob-
ability of R249S positivity using as explanatory 
variables HBsAg status and seasonality adjusted 
for sex and age.
Results
The characteristics of study participants are 
described in Table 1. Most individuals were 
recruited in Keneba and Manduar villages 
(HBsAg positive, 38% and 40%, respectively; 
HBsAg-negative, 52% and 28%). Almost all 
HBsAg-positive subjects had not been vacci-
nated (92%), whereas 44% of HBsAg-negative 
subjects had been vaccinated. Mean serum 
CFDNA concentrations (± SD) were not 
significantly different (p < 0.73) for HBsAg-
positive subjects (0.11 ± 0.92 ng/μL) com-
pared with HBsAg-negative subjects (0.09 ± 
0.51 ng/μL).
A total of 164 subjects (106 HBsAg posi-
tive and 58 HBsAg negative) had R249S serum 
concentrations > 70 copies/mL and were con-
sidered positive for R249S (Table 2). HBsAg-
positive subjects were more likely to be R249S 
positive than HBsAg-negative subjects [45% 
vs. 25%, respectively; odds ratio (OR) = 2.49; 
95% confidence interval (CI): 1.68, 3.69].
Serum R249S concentrations were low 
for both HBsAg-negative and -positive sub-
jects during the higher AFB1 exposure period 
(October–March) (Figure 1). However, during 
the lower AFB1 exposure period (April–July), 
both serum concentrations and the number 
of subjects positive for R249S appeared to 
increase in the HBsAg-positive group.
Mean (± SD) serum concentrations of 
R249S were similar for HBsAg-negative subjects 
during the higher (1,183 ± 5,230 copies/mL 
serum) and lower (400 ± 1,160 copies/mL 
serum) AFB1 exposure periods (p = 0.137) 
and for HBsAg-positive (1,183 ± 5,230 
copies/mL serum) and HBsAg-negative (480 ± 
1,030 copies/mL serum) subjects (p = 0.128) 
during the higher AFB1 exposure period 
(Figure 2). In contrast, the mean serum con-
centration of R249S in HBsAg-positive sub-
jects during the lower AFB1 exposure period 
(5,690 ± 11,300 copies/mL serum) was sig-
nificantly higher than in HBsAg-negative sub-
jects during the same period (p < 0.001) and 
HBsAg-positive subjects during the higher 
AFB1 exposure period (p < 0.001). We also 
observed this seasonal variation when the data 
were analyzed qualitatively (Table 2). The pro-
portion of R249S-positive samples was highest 
among HBsAg-positive subjects during the 
lower AFB1 exposure period (April–July) and 
lowest among HBsAg-negative subjects dur-
ing the same period (61% and 13%, respec-
tively; OR = 10.9; 95% CI: 5.35, 22.34) 
(Table 2). In contrast, the proportions of 
R249S-positive samples were comparable 
between HBsAg-positive and -negative sub-
jects during the higher AFB1 exposure period 
(October–March; 32% and 34%, respectively; 
OR = 0.94; 95% CI: 0.56, 1.57). Thus, in 
HBsAg-positive subjects both the levels of 
Figure 1. Box and whisker plots for the distribution of serum concentrations of TP53 R249S in HBsAg-negative (A) and -positive (B) subjects during higher and lower 
AFB1 exposure periods. Boxes extend from the 25th to the 75th percentile; horizontal lines within the boxes represent the median; whiskers extend 1.5 times the 
length of the interquartile range above and below the 75th and 25th percentiles, respectively; and diamonds represent outliers. Four outliers > 40,000 copies/mL 
serum are not represented: one in March for HBsAg-negative subjects, and one in April and two in June for HBsAg-positive subjects. The number of individuals 
sampled (2–51 subjects/month) and the distribution of HBsAg-positive subjects also positive for the 1762T/1764A double mutation are given.
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R249S in serum (Figure 2) and R249S posi-
tivity (Table 2) peaked several months after 
the previously reported high AFB1 exposure 
period in January–February. In HBsAg-
positive subjects, 61% were R249S positive 
during the lower AFB1 exposure period com-
pared with 32% R249S positive during the 
higher AFB1 exposure period (OR = 3.59; 
95% CI: 2.05, 6.30) (Table 3).
Among HBsAg-pos i t ive  subject s , 
45% were R249S positive, 8% were posi-
tive for the 1762T/1764A HBV mutation, 
and 4% were positive for both R249S and 
1762T/1764A (Table 4). Subjects who had 
both R249S and 1762T/1764A were an aver-
age of 5–11 years younger than other subjects 
[mean age (range) 26 (7–49) years, compared 
with 31 (7–65) years for R249S positive only, 
37 (20–61) years for 1762T/1764A positive 
only, and 31 (5–68) years for negative for 
both mutations]; however, this difference was 
not statistically significant (p = 0.08). Serum 
R249S positivity did not vary significantly 
according to 1762T/1764A status (Table 4), 
village of origin, sex, vaccination status, HBe 
status, or serum concentration of viral DNA 
(data not shown).
HBeAg status and presence of detect-
able HBV DNA also showed seasonal varia-
tion. Among HBsAg-positive subjects, the 
proportion that were HBeAg positive (indi-
cating active viral replication) was highest 
during April–June, whereas the proportion 
with undetectable HBV DNA decreased to 
< 10% between March and May, consistent 
with a seasonal peak in viral replication at the 
transition during high and low AFB1 expo-
sure periods, slightly ahead of the observed 
peak of R249S DNA (Figure 3). The seasonal 
patterns of R249S, HBeAg, and HBV DNA 
were not associated with obvious differences 
in total serum CFDNA concentrations (data 
not shown).
To gain insight into the viral factors that 
may affect the occurrence of R249S in serum, 
we sequenced the entire S gene of HBV 
DNA. A close correlation exists between 
serological subtypes and geno types of HBV 
(Kramvis et al. 2005; Norder et al. 1992, 
2004), and the sequence coding for HBsAg 
can be used for genotyping. We amplified 
the serum DNA of all HBsAg-positive sub-
jects by PCR and obtained non ambiguous 
sequences for 99 subjects, 51 of whom were 
positive for R249S. Among these sequences, 
95 were of geno type E and 4 were of geno-
type A [see Supplemental Material, Figure S1 
(http://dx.doi.org/10.1289/ehp.1103539)]. 
Genotype E sequences were diverse and did 
not represent a particular cluster within the 
current phylogenetic tree of this geno type. A 
total of 15 individuals sequenced for S gene 
were carriers of the 1762T/1764A double 
mutation. To further determine whether the 
presence or level of R249S may vary accord-
ing to particular subgroups, we subdivided 
subjects with sequences belonging to geno-
type E into five groups based on sequence 
similarities. Three distinct S gene sequences 
were found: one in 8 individuals (group 1), 
another in 17 individuals (group 2), and the 
third in 16 individuals (group 3). Group 4 
comprised 12 subjects with closely related 
sequences, and group 5 comprised all other 
subjects (42) with unique S gene sequences. 
We found no significant difference between 
levels of R249S or presence of 1762T/1764A 
double mutation and S sequence groups after 
adjustment for seasonality (data not shown).
Discussion
We used a sensitive and quantitative method 
to detect TP53 R249S in the serum of individ-
uals from a rural area of the Gambia with no 
evidence of chronic liver disease. We obtained 
serum samples in a cross-sectional survey 
performed in 2002–2003 in three villages 
where consumption of AFB1-contaminated 
foodstuff and individual variations in exposure 
to AFB1 have been previously documented 
(Wild et al. 2000). Two matched groups 
of subjects were tested: subjects positive for 
HBsAg (chronic HBV carriers) and control 
subjects sero negative for HBsAg. We detected 
R249S more frequently in HBV carriers (45%) 
than in controls (25%; OR = 2.49; 95% CI: 
1.68, 3.69). In both groups, we observed 
seasonal variations in the proportion of sub-
jects positive for R249S and in the average 
concentration of serum R249S DNA. Our 
results showed that a) R249S was detectable in 
CFDNA of a signifi cant proportion of subjects 
with no symptoms of chronic liver disease; 
b) R249S positivity was associated with HBV 
carrier status; and c) the presence and levels of 
R249S in CFDNA varied according to season.
In the Gambia, groundnut culture occu-
pies > 50% of harvested land (Department 
of Agricultural Services, the Gambia 2008). 
Groundnuts are the main source of exposure 
to aflatoxins and are consumed seasonally 
according to availability. AFB1 accumulates in 
foodstuffs after harvest in September–October 
and peaks in January–February, when the 
Figure 3. Seasonal variation of HBeAg positivity (HBeAg+) and HBV DNA negativity (HBV–) in HBsAg-
positive subjects. The number of individuals sampled each month are given. The value for November 2002 
was not considered because the sample size was too small. 
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Table 3. Subjects positive for serum R249S mutation by HBsAg status [n/total (%)].
HBsAg October–Marcha April–July OR (95% CI)
Negative 45/134 (34) 13/102 (13) 0.30 (0.15, 0.61)
Positive 43/134 (32) 63/103 (61) 3.59 (2.05, 6.30)
ORs are adjusted for age and sex. 
aUsed as reference category for OR determination.
Table 4. HBsAg-positive subjects positive for serum R249S mutation and/or 1762T/1764A double mutation 
[n (%)].
1762T/1764A mutation
R249S mutation status No Yes Total
No 122 (51) 9 (4) 131 (55)
Yes 96 (41) 10 (4) 106 (45)
Total 218 (92) 19 (8) 237 (100)
For 1762T/1764A compared with R249S mutation status, χ2 = 0.5222; p = 0.470. 
AFB1 seasonality-induced TP53 mutation in CFDNA
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availability of stored groundnuts and the rela-
tive lack of other crops lead to significantly 
higher exposure than during other months. 
We did not measure aflatoxin exposure in the 
present study, but the seasonality of expo-
sure is well documented in adults (Wild et al. 
1992) and children (Turner et al. 2000) in 
the Gambia. In addition, Wild et al. (2000) 
reported seasonal variation in AFB1–albumin 
adduct levels in a longitudinal study of 
residents in the same villages included in 
the present study, with the highest level in 
February–March (83.2 pg AFB1-lysine/mg 
albumin; 95% CI: 53.3, 130.8) and the lowest 
levels in June–July (34.9 pg AFB1-lysine/mg 
albumin; 95% CI: 28.5, 42.8). In non-
vaccinated children 3–4 years of age from 
four geographical areas representative of the 
Gambia as a whole, AFB1–albumin adducts 
were detected in all samples (range, 2.2–459 
pg AFB1-lys lysine/mg albumin), and levels 
were twice as high in November–March as in 
May–October (monthly mean levels, 75.7–
88.7 and 27.8–50.3 pg AFB1-lys lysine/mg 
albumin, respectively). Adduct levels were sig-
nificantly higher in acutely and chronically 
HBV-infected children, suggesting that infec-
tion may modulate AFB1 metabolism and 
DNA adduct formation (Wild et al. 2000). 
In the present study, we took this research 
one step further by showing evidence of sea-
sonal variation in the R249S TP53 mutation 
in CFDNA. This mutation is a consequence 
of the formation of AFB1–DNA adducts 
(Besaratinia et al. 2009; Gouas et al. 2009). In 
HBV-negative subjects, temporal patterns were 
similar to those described for AFB1–albumin 
adducts, with a lower proportion positive for 
R249S (13%) among those surveyed dur-
ing April–July (lower AFB1 exposure period) 
than during October–March (34%; higher 
AFB1 exposure period; OR = 0.30; 95% CI: 
0.15, 0.61). In contrast, we observed the oppo-
site pattern in HBV carriers, with a greater 
proportion positive for R249S (61%) among 
those surveyed during April–July than during 
October–March (32%; OR = 3.59; 95% CI: 
2.05, 6.30). Furthermore, the average con-
centration of R249S in serum was higher in 
subjects surveyed in April–July than in those 
sampled in October–March (p < 0.001). The 
process of adduction and fixation of mutation 
and persistence of the mutation require several 
steps, which could partly explain the appar-
ent lag between increased detection of AFB1–
albumin adducts (a short-term biomarker of 
exposure to aflatoxin) and increased detection 
of R249S in CFDNA (which may occur days 
or weeks after exposure). However, taking these 
steps into account does not explain the observed 
difference between controls and HBsAg-positive 
subjects. Therefore, our results suggest that 
the dynamics and persistence of R249S muta-
tions may be different in HBV carriers than in 
controls, consistent with an inter action between 
chronic HBV infection and R249S formation, 
amplification, and persistence.
Positivity for HBeAg and presence 
of detectable HBV DNA in the serum also 
showed seasonal variations, with a peak at the 
transition during periods of high and low AFB1 
exposure. Seasonal reactivation of HBV might 
induce damage to hepato cytes and increase 
R249S release into the bloodstream in the 
weeks that follow reactivation. Seasonal hepati-
tis flare was described by Zhang et al. (2006) in 
a longitudinal study of 2,238 subjects from the 
area of Guangzhou, China. In that study, acute 
exacerbation of hepatitis peaked during spring 
(March–May), and HBeAg sero conversion 
peaked during summer (June–August). So far, 
there is no report on seasonal patterns of HBV 
infection in West Africa.
To gain further insights on the role of 
HBV, we analyzed double mutations in the 
HBV X gene (1762T/1764A) that have been 
associated with infection severity. A recent 
prospective study in Thailand showed that 
chronic HBV carriers with 1762T/1764A dou-
ble mutations had an elevated risk of HCC 
(OR = 2.47; 95% CI: 1.04, 5.85) (Kuang 
et al. 2005). In the Gambia, we observed this 
double mutation in some chronic carriers 
who were asympto matic for chronic liver dis-
ease, and in most HCC or liver cirrhosis cases 
(Mendy et al. 2008). In the present series, 
we found 1762T/1764A double mutations in 
19 of 237 HBV carriers (8%), with no asso-
ciation with R249S positivity. Sequencing of 
the entire S gene in 99 carriers detected geno-
type E in 95 cases and geno type A in four 
cases. We found no association between sub-
groups of geno type E and R249S positivity.
Although there are no data on the stabil-
ity of R249S in serum, its presence at detect-
able levels may require the release of DNA 
from a large number of cells harboring mutant 
DNA. The limited data available on serum 
DNA turnover suggest a very short half-life. 
In a study on fetal DNA in maternal plasma 
after delivery, Lo et al. (1999) estimated the 
mean half-life of circulating fetal DNA to be 
16.3 min (range, 4–30 min). In another study 
evaluating the persistence of Epstein-Barr virus 
DNA in plasma after surgery for nasopharyn-
geal cancer, Chan et al. (2008) found a half-
life of 139 min. Thus, the lag time of several 
months observed between the peak of AFB1 
exposure and the peak of R249S serum levels 
in HBV carriers does not support that the 
release of R249S is the end product of muta-
genesis and a rapid clearance of cells contain-
ing an R249S mutation. If this were the case, 
R249S DNA would occur in the bloodstream 
almost simultaneously to peak AFB1 exposure, 
a scenario seen in controls but not in HBV 
carriers. Thus, our results suggest that, in car-
riers, an interaction between AFB1 exposure 
and HBV might enhance the occurrence, per-
sistence, and/or clonal expansion of cells with 
R249S mutations. In contrast, in controls, 
the formation and release of R249S were con-
sistent with the seasonal pattern of exposure 
to AFB1, which suggests that the presence 
of R249S in the serum of subjects with no 
detectable neoplastic liver lesion may serve as 
a biomarker of muta genesis following dietary 
aflatoxin exposure. TP53 mutation load was 
associated with smoking dose and duration in 
a case–control study of lung cancer (Hagiwara 
et al. 2006), supporting the fact that muta-
tions in CFDNA may serve as reporters of 
diverse forms of carcinogenic exposures.
In a previous case–control study of HCC in 
the Gambia (Lleonart et al. 2005), we showed 
that high plasma concentrations of R249S 
(> 10,000 copies/mL) were associated with 
HCC status (OR = 20; 95% CI: 5.6, 69.0). 
However, traces of R249S (0–2,500 copies) 
were found in many controls. In combination 
with our findings in the present study, results 
suggest that R249S in CFDNA may consti-
tute a biomarker of exposure or a predictor of 
liver cancer, depending upon levels and tem-
poral variation, such that low, transient plasma 
concentrations may reflect seasonal exposure 
to AFB1, whereas high and sustained plasma 
concentrations may indicate the presence of a 
developing cancer lesion. Prospective studies 
on chronic HBV carriers in China have shown 
that R249S concentrations could be detected 
before HCC diagnosis, with a tendency to 
increase in R249S proportion with decreas-
ing time to diagnosis (Jackson et al. 2003; 
Szymañska et al. 2009). Further studies are 
needed to determine quantitative serum R249S 
thresholds as well as time-dependent variations 
that may distinguish subjects with ongoing 
AFB1 exposure from subjects with liver lesions 
progressing toward HCC.
Conclusion
The presence and amount of TP53 R249S 
mutation in serum varied among survey sub-
jects according to season, with a pattern that 
was distinct from the well-known seasonal 
variations in exposure to aflatoxin. Seasonal 
patterns differed between HBV carriers and 
non carriers, suggesting a synergistic effect 
between HBV and aflatoxin exposure. This 
is the first demonstration of such an effect, 
in which being an HBV carrier appears to 
have a profound impact on the persistence of 
mutations induced by aflatoxin. This study 
also demonstrates that, in this particular expo-
sure context, levels of R249S vary seasonally, 
suggesting that this mutation occurs multiple 
times in HBV carriers. A longitudinal study on 
HBV carriers exposed to aflatoxin is needed to 
determine how these variations influence the 
risk of developing chronic liver disease and, 
ultimately, HCC.
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